Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dana-Farber breast oncologists, surgeons, and researchers are participating in the 2019 San Antonio Breast Cancer symposium. Our faculty are sharing results from clinical trials and recent research studies, and are leading a variety of conversations on improving breast cancer care.
Follow along on Twitter: #SABCS19
Schedule of Presentations by Dana-Farber Faculty As leaders in breast cancer research, physicians and scientists from Dana-Farber Cancer Institute are participating in workshops, general sessions, and forums at SABCS 2019. View the schedule of presentations by Dana-Farber faculty for Tuesday through Friday
As leaders in breast cancer research, physicians and scientists from Dana-Farber Cancer Institute are participating in workshops, general sessions, and forums at SABCS 2019.
View the schedule of presentations by Dana-Farber faculty for Tuesday through Friday
Presentations include:
Dana-Farber's Eric P. Winer, MD, Explains Results of HER2CLIMB TrialThis trial looked at a new breast cancer drug called tucatinib, combined with standard therapies.
Ian Krop, MD, PhD, Presents Results from the Phase 2 DESTINY-01 StudyThis study showed how a new antibody-drug conjugate helped prevent cancer progression in women with advanced HER2+ breast cancer.
Sara Tolaney, MD, MPH, Presents Results from the Phase 2 ATEMPT Trial The Phase 2 ATEMPT trial explored a less toxic therapy for early state HER2+ breast cancer.
For SABCS media inquiries, contact John Noble, Media Relations Manager, at johnw_noble@dfci.harvard.edu.